

# 1<sup>st</sup> sohoMENA

SOCIETY OF HEMATOLOGIC ONCOLOGY

[www.sohomena.com](http://www.sohomena.com)

📅 29 & 30 SEPTEMBER, 2023 🇱🇧  
HYBRID EVENT

📍 VENUE: THE LEBANESE NATIONAL LIBRARY  
SANAYEH, BEIRUT, LEBANON

## FINAL PROGRAM



IN COLLABORATION WITH



الجمعية اللبنانية لأمراض الدم و نقل الدم  
LEBANESE SOCIETY OF HEMATOLOGY  
AND BLOOD TRANSFUSION



IN ASSOCIATION WITH



society of hematologic oncology

ORGANIZED BY

Medical  
Communication  
Agency



13  
CME  
CREDITS

**Dear Colleagues and Friends,**

**The Society of Hematologic Oncology (SOHO)** was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

We are proud to organize the **First SOHO for MENA** Region.

This meeting will be in collaboration with the Lebanese Society of Hematology and Blood Transfusion (LSHBT) and Societies of Hematology in MENA countries.

The event will be held in person on September 29<sup>th</sup> and 30<sup>th</sup>, 2023 at the National Library in Sanayeh- Beirut-Lebanon; Those unable to be physically present will have the option to attend virtually.

Advances in leukemias, lymphomas, myeloma, myeloproliferative neoplasms, myelodysplastic syndromes and related malignancies will be highlighted during the official educational program, in addition to "SOHO State of the Art and Next Questions”.

The speakers are a multidisciplinary group of internationally recognized experts that represent the spectrum of these diseases. They are emerging from USA and Europe.

Target Audience are Hematology- Oncology physicians, clinical fellows, research assistants and research fellows, Internal Medicine practitioner, pharmacists, nurses and medical students among other healthcare professionals.

We hope you join the conference and enjoy what Lebanon has to offer from culture, scenery, cuisine, and history.

Sincerely,



**Ahmad Ibrahim, MD, FRCP**  
**President**

Balamand University  
Adj. Lebanese & Beirut Arab Universities  
Ass. American University of Beirut



**Elias Jabbour, MD**  
**Co-Chair**

MD Anderson Cancer Center, USA



**Amer Zeidan, MBBS, MHS**  
**Co-Chair**

Yale School of Medicine, USA



**Rami S. Komrokji, MD**  
**Co-Chair**

Moffit Cancer Center, USA

# CHAIRPERSONS



**Ahmad Ibrahim, MD, FRCP**  
**President**

Dr. Ibrahim is a Professor of Hematology/Oncology at the National Lebanese and Beirut Arab Universities (Lebanon). He is Associate Dean for research at Balamand University, Faculty of Medicine and Medical Sciences (Lebanon).

Dr. Ibrahim obtained his MD from the University of Paris VII-School of Medicine in 1987 and pursued a fellowship in Clinical and Biological Hematology, then a post-fellowship in Bone Marrow Transplantation at the University of Paris and the renowned Fred Hutchinson Cancer Center in Seattle (USA). He was appointed Assistant, then Associate Professor/Senior Attending Physician at the Department of Hematology and Bone Marrow Transplantation Unit at Institute Gustave Roussy, University of Paris (XI) Saclay.

In 1997, Dr. Ibrahim established the first comprehensive Malignant Hematology and Bone Marrow Transplantation Program in Lebanon, at Makassed Hospital-Beirut, affiliated with the Institute Gustave Roussy. Currently, he serves as Chairman of the Department of Internal Medicine and Director of the Bone Marrow Transplant and Cellular Therapy Program at the Middle East Institute of Health (Lebanon), as well as the Chairman of the Department of Hematology/Oncology and Director of the Bone Marrow Transplant and Cellular Therapy Program at Makassed Hospital (Lebanon).

Dr. Ibrahim was a Research Associate at the CNRS (Centre National de la Recherche Scientifique)-UA1156 at the Institute Gustave Roussy, and has been a Research Associate at Lebanese CNRS. He coordinated phase I and II studies in the Department of Hematology at the Institute Gustave Roussy and has participated in several international and national research programs and studies in the field of Hematology/Oncology and Cellular Therapy.

He has been an Associate Director of Research for PhD at the Faculty of Pharmacy-University of Paris V. He was elected as a Core Member of the EORTC-Leukemias Group. He is a member of the Board of Directors of the Eastern Mediterranean Group for Blood and Marrow Transplantation (EMBT).

Dr. Ibrahim has authored and co-authored more than 400 medical publications and book chapters.



**Elias Jabbour, MD**  
**Co-Chair**

Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukemia. Over the past 5 years he has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others. These include: 1) the Hyper CVAD-ofatumumab regimen in ALL; 2) clofarabine in myeloid malignancies; 3) hypomethylating agents in AML and MDS; 4) Tyrosine kinase therapy in CML; and 5) triple therapy in AML. This research has also provided insight into the biology of leukemias. He has extensively addressed the question of resistance to tyrosine kinase inhibitors and to analyze the outcome of these patients. We have identified different mechanisms of resistance and described the clinical significance of them. This has clinical significance in establishing new milestones and leading to personalized therapy. This has tremendous consequences at the scientific and financial levels. He was also actively associated with frontline studies of nilotinib and dasatinib which resulted in FDA approval of these agents for frontline CML therapy in 2010. In addition we have recently addressed the question of genomic instabilities in patients with low-risk MDS who may need earlier therapeutic intervention. This served as a rationale for the first study in the world randomizing such patients to either 5- azacitidine or decitabine. Identifying patients at risk and applying earlier intervention may significantly improve their prognosis. He is leading our efforts to test triple therapy in AML (nucleoside analogs + anthracyclines + cytarabine). The interim results from this randomized trial show a significant improvement in outcome in patients who receive the nucleoside analog clofarabine. This may change the standard of care for the management of patients with AML. Furthermore, I am currently investigating the benefit of adding humanized monoclonal antibody for the treatment of patients with ALL (ofatumumab and HCVAD) and collaborating in the development of monoclonal antibody studies in adult ALL. Finally, he has authored or co-authored hundreds of peer reviewed medical publications and have served on editorial boards of several scientific journals.

# CHAIRPERSONS



**Amer Zeidan, MBBS, MHS**  
**Co-Chair**

Dr. Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division at Yale Cancer Center.

He obtained his medical degree with honors from University of Jordan, followed by residency in Rochester General hospital, Rochester, NY. He then completed a Hematology/Oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation.

Dr. Zeidan has served as the vice chair of the Yale Cancer Center Data and Safety Monitoring Committee (YCC DSMC) and currently serves in the independent data and safety monitoring committees of multiple clinical trials. He is a member of the MyeloMATCH Precision medicine initiative of the National Cancer Institute (NCI) for both MDS and AML. He is very active within the Cancer Therapy Evaluation Program

(CTEP) and Early Therapy Clinical Trial Network (ETCTN) in working on early phase clinical trials of novel therapies for myeloid malignancies. Dr. Zeidan is also active within the International Working Group (IWG) of MDS and has previously served on the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines panel for MDS.

Dr. Zeidan is an author on more than 260 peer-reviewed publications and book chapters.



**Rami S. Komrokji, MD**  
**Co-Chair**

Dr. Komrokji is a Professor of Medicine & Oncologic Sciences at the College of Medicine, at the University of South Florida in Tampa, Florida.

He is the Vice chair of the Malignant Hematology Department and a senior member of the Malignant Hematology and Experimental Therapeutics Program at the Moffitt Cancer Center, Tampa, Florida.

After earning a medical degree in 1996 from the Jordan University School of Medicine, Dr. Komrokji completed an internship and residency at Case Western University, St. Vincent Program. He then completed a fellowship at Strong Memorial Hospital, University of Rochester, in Hematology/Oncology and Hematopoietic Stem Cell Transplantation.

Dr Komrokji is an expert in myeloid neoplasms where he led several clinical trials. His work paved the FDA approval for luspatercept in myelodysplastic syndromes and for Pacritinib in myelofibrosis.

He served as member on the MDS Panel of the National Comprehensive Cancer Network (NCCN) and currently member of the NHLBI MDS natural history study steering committee and aplastic anemia and MDS foundation board of directors.

He has authored or co-authored more than 330 peer-reviewed manuscripts, and 20 book chapters.

# PRESIDENT OF THE LEBANESE SOCIETY OF HEMATOLOGY AND BLOOD TRANSFUSION



**Ali Taher, MD, PhD, FRCP**

Dr. Ali Taher is a prominent figure in the field of hematology and has dedicated his career to advancing the management and treatment of  $\beta$ -thalassemia. He has been invited to over 200 conferences both regionally and internationally as a keynote speaker, chairperson and moderator and has over 509 manuscripts published in leading peer-reviewed international journals (Citations: 23,431; h-index: 75).

At the forefront of Dr. Taher's groundbreaking work is his pioneering research in clinical trials on novel therapeutic agents targeting different aspects of the pathophysiology of  $\beta$ -Thalassemia.

Dr. Taher's contributions also span the realm of iron chelation therapy, a critical aspect of  $\beta$ -thalassemia management. His work on optimizing chelator formulations and assessing patient preferences has reshaped the landscape of iron overload treatment.

Dr. Taher has been acting as a scientific advisor and consultant for the Thalassemia International Federation for years to support all their global efforts to promote optimal care for thalassemia patients through working on clinical, awareness, and education initiatives. He is also an active member of some of the most prestigious Hematology societies in the world including the American Society of Hematology (ASH), and European Hematology Association (EHA). He is currently the chair of the EHA Scientific Working Group (SWG) on Red Cells and Iron, member of the EHA Education committee member of the ASH Scientific Committee on Iron and Heme.

Dr. Taher's influence extends beyond academic roles as he actively took part in leadership positions. Since 2011, Dr. Taher has served as the Vice Chair of Research in the Department of Internal Medicine at AUB. In 2012, he took on the pivotal role of Founding Director of the Fellowship and Residency Research Program (FRRP), contributing to the growth of research initiatives at the Faculty of Medicine. He further showcased his leadership by becoming the Deputy Director and eventually the Director of the Naef K. Basile Cancer Institute (NKBCI) since 2017. In 2021, he added the role of Associate VP for Medical Advancement and Communications.

Dr. Taher's remarkable expertise in the field of research has led to a plethora of awards and honors, including, the prestigious Kuwait Foundation for the Advancement of Sciences (KFAS) Kuwait Prize in 2022, the European Hematology Association (EHA) Education and Mentoring Award in 2022, and the Lifetime Achievement Award in MENA Oncology in 2021. His contributions to thalassemia research have also been recognized regionally and nationally by receiving the International Award for Leadership in Thalassaemia by Sultan Bin Khalifa International Thalassaemia Awards in 2013, the Research Excellence Award by the Lebanese National Council for Scientific Research in 2016 and the Souad Subah Award for Best Scientific Work in 2005. He was also awarded in October 2022 the National Cedar Medal by the Lebanese government in recognition of his contributions to the health and humanitarian fields.

# SCIENTIFIC BOARD



Miguel Abboud, MD



Osama Abu Hlalah, MD



Ahmad Al Askar, MD



Ahmad Al Huraiji, MD



Fatema Al Kaabi, MD



Salam Salim Al Kindi, MD



Salem Al Shammari, MD



Humaid Al Shamsi, MD



Abdala Awidi, MD



Ali Bazarbachi, MD



Amine Bekadja, MD



Nadia Boudjerra, MD



Georges Chahine, MD



Naval Daver, MD



Meletios-Athanasios Dimopoulos, MD



Thierry Facon, MD



Elias Fadel, MD



Bassam Francis, MD



Ashraf Ghandour, MD



Guillermo Garcia-Manero, MD



Khalid Halahleh, MD



Hanan Hamed, MD



# SCIENTIFIC BOARD



Shahrukh Hashmi, MD



Olivier Hermine, MD



Hagop Kantarjian, MD



Jean-Jacques  
Kiladjian, MD



Maha Manachi, MD



Mervat Mattar, MD



Fadi Nasr, MD



Susan O'Brien, MD



Asmaa Quessar, MD



Farhad Ravandi, MD



Giuseppe Saglio, MD



Gilles Salles, MD



Anna Sureda, MD



Ali Taher, MD



Ibrahim Yakoub  
Agha, MD



Pier Luigi Zinzani, MD



# SPEAKERS



Ali Bazarbachi, MD



Guillermo Garcia-Manero, MD



Jean-Jacques Kiladjian, MD



Anna Sureda, MD



Rachid Baz, MD



Olivier Hermine, MD



Rami Komrokji, MD



Ibrahim Yakoub Agha, MD



Claudio Cerchione, MD



Ahmad Ibrahim, MD




Sanam Loghavi, MD



Amer Zeidan, MD



Naval Daver, MD



Elias Jabbour, MD



Susan O'Brien, MD



Pier Luigi Zinzani, MD



Meletios-Athanasios Dimopoulos, MD



Nitin Jain, MD



Farhad Ravandi, MD



Courtney DiNardo, MD



Tapan Kadia, MD



Giuseppe Saglio, MD



Thierry Facon, MD



Hagop Kantarjian, MD



Gilles Salles, MD





<b>08:30-08:45</b>	<b>INTRODUCTION</b> PRESIDENT AND CO-CHAIRS OF SOHO MENA 2023 CONGRESS
	<b>CHRONIC MYELOGENOUS LEUKEMIA</b> <span style="float: right;"><b>CHAIRS:</b> Issam Chehade (LB)   Mohammad Haidar (LB) Bassam Mattar (LB)   Asmaa Quessar (MAR)</span>
<b>08:45-09:00</b>	<b>Frontline Management in CML</b> HAGOP KANTARJIAN
<b>09:00-09:15</b>	<b>Management of Relapsed /Refractory and Advanced Phases in CML</b> ELIAS JABBOUR
<b>09:15-09:30</b>	<b>Treatment – Free Remission in CML</b> GIUSEPPE SAGLIO
<b>09:30-09:40</b>	<b>Next Questions in CML</b> GIUSEPPE SAGLIO
<b>09:40-09:50</b>	<b>Q&amp;A</b>
<b>09:50-11:05</b>	<b>JANSSEN WORKSHOP ON CHRONIC LYMPHOCYTIC LEUKEMIA</b>  <b>CHAIRS:</b> COLETTE HANNA (LB)   AHMAD IBRAHIM (LB) 09:50-10:20 <b>Chronic Lymphocytic Leukemia: Road Map to Cure</b> SPEAKER: ELIAS JABBOUR 10:20-10:30 <b>Q&amp;A</b> 10:30-10:55 <b>Case Presentation on Chronic Lymphocytic Leukemia</b> SPEAKER: ELIAS JABBOUR 10:55-11:05 <b>Q&amp;A</b>

11:05-11:20	<b>Coffee Break</b>	
	<b>ACUTE LYMPHOBLASTIC LEUKEMIA</b>	<b>CHAIRS:</b> Ahmad Al-Askar (KSA)   Jean El Cheikh (LB) Joseph Kattan (LB)   Peter Noun (LB)
11:20-11:35	<b>The Revolution of Immunotherapy in Frontline Management of ALL</b> HAGOP KANTARJIAN	
11:35-11:50	<b>Management of Philadelphia positive ALL</b> ELIAS JABBOUR	
11:50-12:05	<b>Antibodies, CAR-T and Novel Agents in Relapsed / Refractory ALL</b> ELIAS JABBOUR	
12:05-12:20	<b>Minimal Residual Disease Assessment in ALL and Management</b> FARHAD RAVANDI	
12:20-12:30	<b>Next Questions in ALL</b> ELIAS JABBOUR	
12:30-12:40	<b>Q&amp;A</b>	

**MYELOPROLIFERATIVE NEOPLASMS**

**CHAIRS:** Mona Ayoubi (LB) | Christina Khater (LB)  
Jawad Makarem (LB) | Ahmad Chahrour (LB)

<b>12:40-12:55</b>	<b>Update on the Classification of MPNs</b> RAMI KOMROKJI
<b>12:55-13:10</b>	<b>Management of Myelofibrosis: 2023 Updates</b> JEAN-JACQUES KILADJIAN
<b>13:10-13:25</b>	<b>Next Questions in MPNs</b> JEAN-JACQUES KILADJIAN
<b>13:25-13:30</b>	<b>Q&amp;A</b>
<b>13:30-14:00</b>	<b>Lunch</b>
<b>14:00-14:30</b>	<b>CHAIR:</b> BIROL GÜVENC (TUR) <b>PHARMAMED Symposium: Management of Relapsed/ Refractory diffuse large B cell Lymphoma</b> <b>SPEAKER:</b> AHMAD IBRAHIM

## ACUTE MYELOBLASTIC LEUKEMIA

**CHAIRS:** Iman Abou Dalle (LB) | Bassam Francis (IRQ)  
Maha Manachi (SYR) | Fadi Nasr (LB)

<b>14:30-14:45</b>	<b>Frontline Therapy in AML</b> FARHAD RAVANDI
<b>14:45-15:00</b>	<b>Management of AML in Elderly</b> AMER ZEIDAN
<b>15:00-15:15</b>	<b>Targeted Therapy and New Agents in AML</b> NAVAL DAVER
<b>15:15-15:30</b>	<b>BCL2 Inhibitors in AML</b> COURTNEY DINARDO
<b>15:30-15:45</b>	<b>Minimal Residual Disease Assessment in AML and Maintenance Therapy</b> TAPAN KADIA
<b>15:45-15:55</b>	<b>Next Questions in AML</b> TAPAN KADIA
<b>15:55-16:05</b>	<b>Q&amp;A</b>

## MYELODYSPLASTIC SYNDROMES

**CHAIRS:** Salam Al-Kindi (OM) | Hanan Hamed (EGY)  
Khalid Halahleh (JOR) | Joseph Makdessi (LB)

<b>16:05-16:20</b>	<b>Update on the Classification, Response Criteria and Prognosis in MDS</b> RAMI KOMROKJI
<b>16:20-16:35</b>	<b>Management of High-risk MDS</b> GUILLERMO GARCIA-MANERO
<b>16:35-16:50</b>	<b>Management of Low-risk MDS</b> AMER ZEIDAN
<b>16:50-17:05</b>	<b>Management of TP53 MDS/AML</b> GUILLERMO GARCIA-MANERO
<b>17:05-17:15</b>	<b>Next Questions in MDS</b> GUILLERMO GARCIA-MANERO
<b>17:15-17:25</b>	<b>Q&amp;A</b>
<b>17:25-17:40</b>	<b>Coffee Break</b>

**CHRONIC LYMPHOCYTIC LEUKEMIA**

CHAIRS: Ahmad Al- Mashhadani (IRQ) | Mirna El Hajj (LB)  
Oussama Safar (LB) | Ahmad Younes (LB)

<b>17:40-17:55</b>	<b>Frontline Therapy in CLL</b> NITIN JAIN
<b>17:55-18:10</b>	<b>Management of Relapsed / Refractory CLL</b> SUSAN O'BRIEN
<b>18:10-18:25</b>	<b>Minimal Residual Disease in CLL and Management</b> NITIN JAIN
<b>18:25-18:35</b>	<b>Next Questions in CLL</b> SUSAN O'BRIEN
<b>18:35-18:45</b>	<b>Q&amp;A</b>

CHAIRS: MIGUEL ABBOUD (LB) | MERVAT MATTAR (EGY)

**18:45-19:05**

**Plenary Session: Hereditary Leukemia Syndromes**  
COURTNEY DINARDO

**19:05-19:35**

CHAIR: GEORGES EL HACHEM (LB)

**MERSACO Symposium: Management of Relapsed Myeloma**  
SPEAKER: ALI BAZARBACHI

**19:35-20:00**

**OPENING CEREMONY & EXHIBIT VISIT**

**LYMPHOMA**

**CHAIRS:** Nadia Boudjerra (ALG) | Nabil Chamseddine (LB)  
Ahmad Al-Hamandi (IRQ) | Ali Youssef (LB)

<b>09:00-09:15</b>	<b>Management of Follicular Lymphoma : 2023 Updates</b> PIER LUIGI ZINZANI
<b>09:15-09:30</b>	<b>Management of Mantle Cell Lymphoma : 2023 Updates</b> OLIVIER HERMINE
<b>09:30-09:50</b>	<b>Management of Diffuse large B cell Lymphoma: Revolutions in Frontline, CAR-T and Bispecific Antibodies</b> GILLES SALLES
<b>09:50-10:05</b>	<b>Management of Peripheral T Cell Lymphoma: 2023 Updates</b> PIER LUIGI ZINZANI
<b>10:05-10:20</b>	<b>Management of Hodgkin’s Lymphoma: 2023 Updates</b> ANNA SUREDA
<b>10:20-10:30</b>	<b>Next Questions in Lymphoma</b> ANNA SUREDA
<b>10:30-10:40</b>	<b>Q&amp;A</b>
<b>10:40-10:55</b>	<b>Coffee Break</b>
<b>10:55-11:25</b>	<b>CHAIR: AHMAD IBRAHIM (LB)</b> <b>ROCHE Symposium: Updates in the Management of DLBCL Patients</b> <b>SPEAKER: ALI BAZARBACHI</b>

**HEMATOPATHOLOGY & MOLECULAR BIOLOGY**

**CHAIRS:** Alaa Fadhil Alwan (IRQ) | Hampig Kourieh (LB)  
Rami Mahfouz (LB) | Hanadi Samaha (LB)

<b>11:25-11:45</b>	<b>Navigating Change: Integrating WHO/ICC Classification Systems in the Management of Patients with Myelodysplastic Syndromes/Neoplasms</b> SANAM LOGHAVI
<b>11:45-12:00</b>	<b>Why Acute Myeloid Leukemia with a FLT3 Internal Tandem Duplication is no More Categorized at High Risk but at Intermediate Risk?</b> ALI BAZARBACHI
<b>12:00-12:20</b>	<b>Diagnostic and Molecular Work-up of Newly Diagnosed Acute Myeloid Leukemia- The Pathologists' Perspective</b> SANAM LOGHAVI
<b>12:20-12:30</b>	<b>Q&amp;A</b>
<b>12:30-12:50</b>	<b>CHAIRS:</b> Abdalla Awidi (JOR)   Ahmad Ibrahim (LB) <b>Plenary Session: Immunotherapy in Leukemia</b> NAVAL DAVER
<b>12:50-13:20</b>	<b>CHAIR:</b> ALI BAZARBACHI (LB) <b>JANSSEN Symposium: New Treatment Paradigms in Multiple Myeloma</b> <b>SPEAKER:</b> RACHID BAZ
<b>13:20-13:30</b>	<b>Q&amp;A</b>
<b>13:30-14:00</b>	<b>Lunch</b>



**MULTIPLE MYELOMA & RELATED DISEASE**

**CHAIRS:** Osama Jradi (LB) | Amine Bekadja (ALG)  
Khaled Ibrahim (LB) | Therese Abou Nasr (LB)

<b>14:00-14:15</b>	<b>First line Treatment of Newly Diagnosed Multiple Myeloma in Fit Patients and Role of Autologous Transplantation</b> RACHID BAZ
<b>14:15-14:30</b>	<b>First line Treatment of Newly Diagnosed Multiple Myeloma Non Eligible for Autologous Transplantation</b> THIERRY FACON
<b>14:30-14:45</b>	<b>The Revolution of Bispecific Antibodies and CAR-T in Multiple Myeloma</b> IBRAHIM YAKOUB AGHA
<b>14:45-15:00</b>	<b>Minimal Residual Disease Assessement in Multiple Myeloma</b> MELETIOS-ATHANASIOS DIMOPOULOS
<b>15:00-15:10</b>	<b>Management of Amyloidosis: 2023 Updates</b> MELETIOS-ATHANASIOS DIMOPOULOS
<b>15:10-15:25</b>	<b>Management of Smoldering Multiple Myeloma</b> CLAUDIO CERCHIONE
<b>15:25-15:35</b>	<b>Next Questions in Multiple Myeloma</b> RACHID BAZ
<b>15:35-15:45</b>	<b>Q&amp;A</b>

<b>15:45-16:00</b>	<b>Coffee Break</b>
<b>16:00-16:30</b>	CHAIR: ZAHERA FAHED (SYR) <b>SANDOZ Symposium: Rixathon Clinical Trials and Real World Data</b> SPEAKER: AHMAD IBRAHIM
<b>16:30-17:30</b>	FACILITATOR: AHMAD IBRAHIM (LB) <b>INTERACTIVE ROUND TABLE WITH EXPERTS</b> CO-CHAIRS: OSAMA ABU HLALAH (JOR)   KHALIL SALEH AL FARSI (OM)   AHMAD AL HURAIJI (KWT)   SERDAR BEDII OMAI (TUR)
<b>17:30-18:30</b>	<b>INTERACTIVE SESSION: PATIENTS, HEALTHCARE PROVIDERS AND SYSTEMS AND POLITICS</b> AHMAD IBRAHIM (LB)   MARCEL MASSOUD (LB)   WAJIH SAAD (LB)
<b>18:30-18:45</b>	<b>Closing Remarks/ Adjourn</b> PRESIDENT & CO-CHAIRS OF SOHO MENA 2023 CONGRESS

✂ **Twitter: @sohomena**  
#SOHOMENA #SOHOMENA23

**Scan barcode to register**  
For more information please visit:  
[www.sohomena.com](http://www.sohomena.com)



Medical  
Communication  
Agency  
[+961] 1446 958  
[www.M2Med.org](http://www.M2Med.org)



# SOHO MENA 2023

## VENUE | THE LEBANESE NATIONAL LIBRARY

In 1999, by decision of the Council of Ministers, the building of the Faculty of Law and Political Sciences of the Lebanese University, located in the district of Sanayeh, was allocated to the Lebanese National Library


Its Located in the heart of Beirut at Ramlet al-Zarif, the Sanayeh (Crafts) building is part of a large complex that originally comprised a Hospital in the West (now the Ministry of Interior) and the School of Arts and Crafts in the East (future National Library), facing a large public garden (the Garden of Sanayeh).

This complex was built during the reign of Sultan Adulhamid II, hence the initial name of the buildings: Hamidian School and Hamidian Hospital. The first stone was laid in September 1905 and the construction was completed in 1907.

Ahmad Abbas al-Azhari was the initiator and director of the Arts and Crafts School whose primary mission was to provide practical lessons in arts and crafts to needy children who aspired to work in trade or industry. Both buildings were officially launched on August 19, 1907, by the Wali Khalil Pacha, governor of Beirut, to mark the birthday of the Sultan Abdulhamid II, in the presence of foreign consuls and prominent citizens of the city. It was the largest urban development project at the time in the provincial capital of Beirut.



[CLICK HERE FOR DIRECTIONS](#)



# SPONSOR ACKNOWLEDGEMENT

THE FIRST SOHO MENA WISHES TO EXPRESS ITS GRATITUDE TO THE FOLLOWING CORPORATE SPONSORS:

## PLATINUM SPONSOR

---



PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*

## GOLD SPONSORS

---



## SILVER SPONSORS

---

pAYME  
1m ago  
You've just



## BRONZE SPONSORS

---



## CONTRIBUTORS

---

